Clinical Trials Browser

INDUSTRY × Has announcements × Lymphoma, Large B-Cell, Diffuse × Clear all

NCT04404283 2026-03-17

ECHELON-3

Phase 3 Active not recruiting

238 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03274492 2026-02-06

POLARIX

Phase 3 Active not recruiting

1,000 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03391466 2025-12-01

ZUMA-7

Phase 3 Completed

359 enrolled 27 charts 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT02227251 2025-10-01

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Recruiting

244 enrolled 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT02631044 2024-06-27

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Phase 1 Completed

387 enrolled 2 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02445248 2024-04-18

JULIET

Phase 2 Completed

115 enrolled 22 charts 1 FDA

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01897571 2024-03-26

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Phase 1/2 Completed

400 enrolled 22 charts 2 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03483103 2023-12-20

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

Phase 2 Completed

74 enrolled 43 charts 1 FDA

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02399085 2023-10-23

L-MIND

Phase 2 Completed

81 enrolled 23 charts 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT02793583 2022-07-21

UNITY-NHL

Phase 2/3 Terminated

710 enrolled 1 FDA

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell